El interés en corto de Intellia Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Intellia Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Intellia Therapeutics (NASDAQ:NTLA) Bolsa, Informe de interés en corto

INTELLIA THERAPEUTICS INC

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

News

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

ILMN

NTLA

OKLO

PATH

Descubre las recientes decisiones de Ark Invest en energía, defensa y genética, con transacciones millonarias en empresas clave.

Ark Invest adquiere y vende acciones clave en energía, defensa y tecnología genética

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) ("VivoPower" or the "Company") announced today that its independent directors have approved the commencement of a shareholder debt principal reduction plan. The initial repayment was made to AWN Holdings Limited ("AWN") on July 3, 2025. AWN, a private investment office, is backed by a member of Dubai's Al Maktoum ruling family, signalling institutional and sovereign wealth funding support for VivoPower and its growth objectives.
The unaudited balance of the principal component of the AWN shareholder loan was $28.8 million as of June 30, 2025.
The Company's objective is to retire the AWN shareholder loan in full. This initiative reflects VivoPower's long term commitment to strengthening its balance sheet and optimizing its capital structure, while ensuring adequate financial capacity to support its transformational growth strategies. Execution of this objective remains subject to ongoing approval from the Company's independent directors and the availability of sufficient liquidity.

VVPR

VivoPower's Independent Directors Approve Commencement Of Shareholder Debt Principal Reduction Plan

Shares of Geo Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) and CoreCivic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) are popping on Monday following last week's <a href="https://www.benzinga.com/news/politics/25/07/46255065/trumps-3-3-trillion-bill-passes-will-vulnerable-americans-pay-the-price">Congressional approval</a> of President Donald Trump's massive tax and spending bill, which vastly increases funds for the administration's aggressive <a href="https://www.benzinga.com/news/politics/25/06/46110499/trumps-big-beautiful-bill-to-inject-150-billion-into-immigration-enforcement-over-the-next-four-years-report">immigration policy</a>.
What's happening? As the country's two largest private prisons and contractors with the now-expanding immigrant detention centers, their fortunes seem to be securely on the rise.
In keeping with a popular campaign promise, Trump's so-called "Big Beautiful Bill" will triple federal spending on immigrant detention by earmarking $45 billion over the next four years. That's more than the Obama, Biden and first Trump administrations spent combined.
Read also: <a href="https://www.benzinga.com/news/politics/25/07/46257635/trump-administrations-ice-raids-compared-with-wwii-japanese-internment-camps-by-george-takei-politicians-lie-and-people-believe-that-lie">Trump Administration&#8217;s ICE Raids Compared With WWII Japanese Internment Camps By George Takei: &#8216;Politicians Lie, And People Believe That Lie&#8217;</a>
Trump's tax bill, <a href="https://www.washingtonpost.com/business/2025/07/04/trump-bill-ice-immigrant-detention/">notes</a> the Washington Post, also earmarks $46.5 billion for construction of the unfinished U.S.-Mexico border wall and $6 billion for surveillance and border technology.
Officials at U.S. Immigration and Customs Enforcement (ICE) said the funding would allow them to roughly double detention capacity to 100,000 beds and expand their ability to detain undocumented immigrants. ICE has awarded new or extended contracts this year to at least nine facilities operated by Geo Group and CoreCivic, along with others managing tent-based detention centers.
"This bill will make our communities safer by making a historic investment in our border security," <a href="https://www.washingtonpost.com/business/2025/07/04/trump-bill-ice-immigrant-detention/">said</a> Rep. Addison McDowell. "No more dangerous illegal aliens parading around with no consequences."
Nationwide, ICE had detained 56,397 immigrants as of June 15, the highest number on record since the agency began disclosing such data and far above its funded capacity of 41,500, <a href="https://www.cato.org/blog/65-people-taken-ice-had-no-convictions-93-no-violent-convictions" target="_blank" rel="noreferrer noopener">according to the Cato Institute</a>. 
Rep. Alexandria Ocasio-Cortez (D-NY) has taken the <a href="https://www.benzinga.com/news/25/05/45378544/trump-administration-funneling-money-to-private-prison-companies-aoc-says-calling-out-profits-from-ice-detentions-after-campaign-kickbacks">Trump administration to task</a> on various occasions for what she describes as a massive financial windfall for private prison companies, accusing them of prioritizing profits over humane conditions for detainees.&nbsp;
Other lawmakers have called the ICE-directed cash "budgetary mismanagement" after funds had to be redirected from other departments.
Now Read: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46205574/trump-desantis-alligator-alcatraz-immigrant-detention-center-florida-everglades">Trump And DeSantis Inaugurate &#8216;Alligator Alcatraz&#8217; Immigrant Detention Center Deep In Florida Everglades</a></li>
</ul>
Photo: Shutterstock

Government

Politics

Trading Ideas

Trump's $45-Billion Immigration Policy Supercharges Profits For Private Prisons Under 'Big Beautiful Bill'

WIIM

LCID

PSNY

RIVN

Shares of EV stocks are trading lower following the signing of Trump's 'Big Beautiful Bill,' which will remove the $7,500 tax credit for new US-made EVs.

Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares are down more than 2% Monday, pulling back after climbing more than 16% over the past month. Here&#8217;s a look at what could be fueling <a href="https://www.benzinga.com/node/45955190">the recent run</a>.
What To Know: AMD shares have been trading on strong momentum since late April. The rally accelerated last month following a series of product launches at AMD's "Advancing AI" event. 
Piper Sandler analyst Harsh Kumar maintained AMD with an <a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noreferrer noopener">Overweight rating</a> and raised the price target from $125 to $140 following the event, noting that the company&#8217;s <a href="https://www.benzinga.com/markets/tech/25/06/45919591/amd-challenges-nvidias-ai-dominance-with-new-helios-server-as-openai-ceo-sam-altman-confirms-chatgpt-will-use-lisa-su-led-tech-giants-latest-chips-future-of-ai-is-not-going-to-be-built-b" target="_blank" rel="noreferrer noopener">Helios rack announcement</a> would be "pivotal" for AMD Instinct growth moving forward.
The Piper Sandler analyst also said he was optimistic that the company's GPU business was trending in the right direction and should see a "snapback" in the fourth quarter.
Several other analysts maintained bullish ratings and price targets following the event. Rosenblatt maintained a Buy rating and price target of $200, Benchmark reiterated Buy with a price target of $170, Roth Capital maintained a Buy rating and raised its price target to $150 and Evercore ISI Group maintained an Outperform and lifted its target to $144. 
Last week, Mizuho maintained an Outperform and raised its price target to $152 and Citigroup on Monday maintained a Neutral rating and lifted its price target to $145.
The consensus price target for AMD is $141.60, with the lowest price target sitting at $95 and the highest price target currently at $200.
<h3 class="wp-block-heading">How To Buy AMD Stock</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in AMD's case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46269226/stocks-just-hit-rare-golden-cross-for-1st-time-since-2023-heres-what-it-means-for-investors">Stocks Just Hit Rare Golden Cross For 1st Time Since 2023 — Here&#8217;s What It Means For Investors</a>
AMD Price Action: At the time of publication, AMD shares are trading 2.14% lower at $134.97, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro</a>.
Image via Shutterstock

Price Target

Movers

What's Going On With AMD Stock?

Citigroup analyst Christopher Allen maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Buy and raises the price target from $102 to $105.

Analyst Ratings

SCHW

Citigroup Maintains Buy on Charles Schwab, Raises Price Target to $105

Citigroup analyst Christopher Allen maintains Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) with a Neutral and raises the price target from $94 to $115.

Citigroup Maintains Neutral on Stifel Financial, Raises Price Target to $115

Citigroup analyst Christopher Allen maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Neutral and raises the price target from $50 to $100.

HOOD

Citigroup Maintains Neutral on Robinhood Markets, Raises Price Target to $100

Citigroup analyst Christopher Allen maintains Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) with a Neutral and raises the price target from $150 to $165.

Citigroup Maintains Neutral on Raymond James Finl, Raises Price Target to $165

Real estate investor Grant Cardone built a multi-billion-dollar real estate portfolio with leverage, hard work, connections, and other essentials. However, he recently discussed his <a href="https://www.tiktok.com/@grantcardone/video/7522155298979581198?lang=en">relationship with money</a>, and it offers a clear perspective into Cardone's success. He doesn't put it up on the altar, but Cardone takes money very seriously and encourages others to do the same.
"The way you treat money is how the money's going to treat you," he explained.
Your mentality toward money affects your income, investments, expenses, and every other part of your life that money touches. Here's how you can strengthen your relationship with money so you can boost your income and net worth.
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
<h2 class="wp-block-heading">Respect Money But Don't Let It Consume You</h2>
Cardone accumulates money and puts it into real estate because he wants the money to multiply. While he spends money as well, he makes it a point to spend money on tax write-offs. His shirts have his company's branding on them, so when he buys those shirts, he gets to write them off.
If you get deep into credit card debt, you are letting money consume you. The deeper you get into debt, the more difficult it becomes to claw your way out. Interest payments accumulate quickly, and while some debt can be good, credit card debt never qualifies as good debt. The interest rates are too high.
Cardone also views financial success as one facet of a successful life. He also commits to his family, exercise, spirituality, and other areas of his life. There's more to Cardone than being wealthy and increasing his net worth. Some people who are successful financially get divorced because they prioritize money above everything else. That's another example of letting money consume you, which Cardone advises against.
Trending: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
<h2 class="wp-block-heading">The Most Important Money Cardone Ever Made&nbsp;</h2>
The conversation eventually shifted to Cardone's work as a car salesman. The job had long hours, and he dealt with plenty of rejection. You have to get on the phone a lot to be a successful car salesman, and long hours don't necessarily equate to success.
Cardone despised the job, but it was one of the few opportunities open to him at the time. That job set up Cardone for a successful sales career and a real estate empire, and he explains that making his first $1,000 at the company set him on his current path.
Cardone realized that he was in control of his money and income growth the moment he made $1,000 and then jumped to $2,000 and $3,000 per month. He used that momentum to excel as a salesperson, seek new opportunities, and claim control over his finances.
See Also: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>
<h2 class="wp-block-heading">You Are In Control Of Your Income</h2>
Cardone's last message about controlling your income explains why he's become successful, but it also offers a valuable insight for viewers. When you put yourself in the driver's seat, you give yourself more options.
People can pursue side hustles, ask for raises, job hop, or start a business to boost their income. You don't have to stay in one place forever or let one person dictate how much you earn.&nbsp;
Developing new skills and meeting new people can lead to a higher income. However, your relationship with money plays a key role in how successful you are with those actions. If you are firmly committed to good money habits like keeping expenses low and investing most of your paycheck, you will put yourself in a better position to increase your income.&nbsp;
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Personal Finance

'The Way You Treat Money Is How The Money's Going To Treat You' -- Grant Cardone Discusses Taking Control Of Your Income

Honda shares are trading lower after President Trump announced tariffs on imports from Japan and Korea.

Citigroup analyst Atif Malik maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy and raises the price target from $87 to $108.

LRCX

Citigroup Maintains Buy on Lam Research, Raises Price Target to $108

Macro Notification

General

Reuters Cites EU Sources Saying EU Looking Into Possible Deal On Cars To Offset U.S. Car Exports Against Imports; EU May Secure Baseline Tariff Exemptions For Aircraft, Spirits In U.S. Trade Deal

Citigroup analyst Atif Malik maintains KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Buy and raises the price target from $835 to $1035.

KLAC

Citigroup Maintains Buy on KLA, Raises Price Target to $1035

SoFi Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) shares are trading higher Monday, hitting a new <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46206403/why-sofi-technologies-stock-was-a-top-performer-in-june">52-week high of $19.29.</a>
What To Know: SoFi shares are up approximately 33% over the past month on continued momentum that saw the stock climb to new 52-week highs on Monday.
Last month, SoFi's CFO Chris Lapointe reaffirmed the company's financial targets at the William Blair Growth Stock Conference, projecting adjusted net revenue to exceed $3 billion by 2025 and annual growth above 25% through 2026. The bullish targets appeared to help add to the momentum in the fintech stock.
SoFi also announced a new push into digital assets late last month. SoFi confirmed plans to introduce cryptocurrency trading later this year, including in assets like Bitcoin and Ethereum. The company said it also plans to offer new crypto-backed loans and cross-border payment tools and broaden its offerings to stablecoins. CEO Anthony Noto also emphasized that blockchain technology would be integrated across SoFi's entire suite of services.
Truist Securities initiated coverage in early June with a Hold rating and a $14 price target. Other recent analyst coverage includes a price target increase to $12 from Barclays and a price target hike to $15.50 from UBS. Sofi has a Street-high target of $20 and a consensus analyst target of $11.31, according to Benzinga <a href="https://www.benzinga.com/quote/SOFI/analyst-ratings">analyst data</a>. 
SoFi also has short interest of approximately 13.6%, which may be helping fuel some of the recent rally in shares. The company scheduled its second-quarter earnings for July 29 last week. Analysts currently expect the company to report earnings of 6 cents per share and revenue of $801.49 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
SOFI Price Action: <a href="http://benzinga.com/quote/sofi">SoFi Technologies shares</a> were up 2.95% at $19.12 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46281204/wall-street-today-trump-tariffs-japan-south-korea-stocks-drop">Wall Street Slumps, Dollar Jumps After Trump&#8217;s Tariff Blitz: What&#8217;s Moving Markets Monday?</a></li>
</ul>
Image Via Shutterstock.

SOFI

SoFi Technologies Stock Hits 52-Week High: What's Driving The Momentum?

Citigroup analyst Atif Malik maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and raises the price target from $190 to $220.

AMAT

Citigroup Maintains Buy on Applied Mat, Raises Price Target to $220

<a href="https://www.businessinsider.com/tiktok-owner-bytedance-plans-create-a-us-version-of-capcut-2025-7?utm_campaign=business-sf&amp;utm_source=twitter&amp;utm_medium=social">https://www.businessinsider.com/tiktok-owner-bytedance-plans-create-a-us-version-of-capcut-2025-7?utm_campaign=business-sf&amp;utm_source=twitter&amp;utm_medium=social</a>

AMZN

ORCL

PINS

SNAP

'TikTok's owner has plans to move US users to a new version of CapCut, the popular video-editing app'- Business Insider

Citigroup analyst Christopher Danely maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Buy and raises the price target from $220 to $260.

Citigroup Maintains Buy on Texas Instruments, Raises Price Target to $260

Live On CNBC, Kevin Simpson Announces Added To Boeing Position

Citigroup analyst Christopher Danely maintains Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) with a Neutral and raises the price target from $145 to $170.

QCOM

Citigroup Maintains Neutral on Qualcomm, Raises Price Target to $170

GE Vernova shares are trading higher after UBS initiated coverage with a Buy rating and a price target of $614.

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA

Legal

Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLA

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Health Care

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Comments

Intellia Therapeutics

Interés en corto

Intellia Therapeutics (NASDAQ:NTLA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL